We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$246M
AUM Growth
-$23.5M
Cap. Flow
+$1.47M
Cap. Flow %
0.6%
Top 10 Hldgs %
97.51%
Holding
22
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
VNRX icon
VolitionRx Ltd
VNRX
+$1.73M

Top Sells

Rank Stock Value
1
ENLV icon
Enlivex Ltd
ENLV
+$260K

Sector Composition

Rank Sector Weight
1 Healthcare 17.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$202M 82.11%
4,397,838
– –
TOVX icon
2
Theriva Biologics
TOVX
$10.2M
$8.81M 3.58%
427
– –
AMPE
3
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$7.62M 3.1%
11,294
– –
CRBP icon
4
Corbus Pharmaceuticals
CRBP
$170M
$4.64M 1.88%
85,464
– –
ARCT icon
5
Arcturus Therapeutics
ARCT
$157M
$4.23M 1.72%
159,331
– –
ABEO icon
6
Abeona Therapeutics
ABEO
$345M
$3.48M 1.41%
54,391
– –
CEMP
7
DELISTED
Cempra, Inc.
CEMP
$3.17M 1.29%
180,800
– –
ADXS
8
DELISTED
Advaxis Inc
ADXS
$2.48M 1.01%
18,333
– –
LUMO
9
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.86M 0.76%
11,382
– –
VNRX icon
10
VolitionRx Ltd
VNRX
$12M
$1.64M 0.67%
+23,077
New +$1.73M
KERX
11
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$934K 0.38%
200,000
– –
ADXSW
12
DELISTED
Advaxis Inc Warrants
ADXSW
$677K 0.27%
112,500
– –
NBSE
13
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$658K 0.27%
513
– –
ENLV icon
14
Enlivex Ltd
ENLV
$70.7M
$625K 0.25%
418
-146
-26% -$260K
ALDX icon
15
Aldeyra Therapeutics
ALDX
$91.7M
$569K 0.23%
135,800
– –
LSTA icon
16
Lisata Therapeutics
LSTA
$15.2M
$417K 0.17%
3,705
– –
CSBR icon
17
Champions Oncology
CSBR
$85.1M
$405K 0.16%
111,111
– –
GLMD icon
18
Galmed Pharmaceuticals
GLMD
$3.94M
$320K 0.13%
361
– –
EVOK
19
DELISTED
Evoke Pharma
EVOK
$283K 0.11%
387
– –
ZSAN
20
DELISTED
Zosano Pharma Corporation
ZSAN
$43K 0.02%
27
– –
APTO
21
DELISTED
Aptose Biosciences, Inc.
APTO
$34K 0.01%
27
– –

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Knoll Capital Management held 22 positions worth $246M, down 8.7% from $270M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Trading was light in Q1 2016: portfolio turnover was 4.5%. Knoll Capital Management opened 1 new position and made no exits, leaving the 22-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 20% a quarter earlier.

  • Knoll Capital Management's largest Q1 2016 buy was VolitionRx Ltd: 23,077 shares worth $1.64M.
  • Knoll Capital Management's biggest Q1 2016 reduction was Enlivex Ltd, cutting an estimated $260K.
  • Knoll Capital Management's ten largest holdings make up 98% of its $246M portfolio in Q1 2016.
  • Knoll Capital Management opened 1 new position and closed 0 in Q1 2016.
  • Knoll Capital Management's portfolio value fell 8.7% quarter-over-quarter to $246M.

Based on Knoll Capital Management's 13F filing for Q1 2016, filed 16 May 2016.